Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
#GLP1 #ObesityResearch #Metabolism #AppetiteRegulation #DiabetesResearch #Liraglutide #Semaglutide #Novonordisk #inflammation #markfriedman To view or add a comment, sign in India approves Novo Nordisk's obesity drug #Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (#MASH), a serious form of fatty liver disease
Martin Khrmann: Nothing to disclose
doi: 10.3389/fimmu.2024.1466023 Received 17 July 2024 Accepted 09 September 2024 Published 25 September 2024 Volume 15 - 2024 Edited by Reza Akbarzadeh, University of Lbeck, Germany Reviewed by Maximiliano Jimenez Dalmaroni, National University of La Plata, Argentina Bernhard Ryffel, Centre National de la Recherche Scientifique (CNRS), France Jrmie Decalf, Genentech Inc., United States Updates Copyright 2024 Zhu and Zhou
There is also a need to determine whether these results translate to humans
10.1016/j.celrep.2021.108947 Cell Rep
